Why carry out this study?

Mitomycin-C (MMC) has antifibrotic effects on the nasal mucosal fibroblasts and can improve success of external or endonasal dacryocystorhinostomy (DCR). However, there are conflicting opinions about this

The present study is an up-date meta-analysis to determine whether this adjuvant therapy results in better surgical outcomes in the treatment of primary acquired nasolacrimal duct obstruction

What was learned from the study?

Intraoperative use of MMC as an adjunctive treatment for external or endonasal DCR is safe and effective in increasing the success rate of the procedure

Despite the favorable results, the evidence was very weak. Thus, further controlled trials with a large sample size are needed to evaluate the optimum concentration as well as exposure time and application mode